Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Paper citation network

Psilocybin use in Puerto Rico: Patterns, motivations, and personality correlates from an online survey

Vélez Rodríguez Jean C., Duquesne-Maldonado Yanice, Hernández Torres Julián M., Da'Luz Sant'Ana Istoni, Nazario Cruz M.

Publication record · Explore literature

Public tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.

References — this paper cites (63)

  1. Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder. 2025-01-01 · Expand citations
  2. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. 2024-01-01 · Expand citations
  3. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. 2022-10-01 · Expand citations
  4. Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. 2022-04-01 · Expand citations
  5. Psilocybin for Trauma-Related Disorders. 2022-01-01 · Expand citations
  6. Use of psilocybin (“mushrooms”) among US adults: 2015-2018 2021-02-04 · Expand citations
  7. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. 2020-02-01 · Expand citations
  8. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. 2019-05-01 · Expand citations
  9. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. 2018-11-01 · Expand citations
  10. Potential Therapeutic Effects of Psilocybin. 2017-07-01 · Expand citations
  11. Psilocybin for treating substance use disorders? 2017-02-01 · Expand citations
  12. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. 2016-12-01 · Expand citations
  13. Return of the psychedelics: Psilocybin for treatment resistant depression. 2016-12-01 · Expand citations
  14. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016-07-01 · Expand citations
  15. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 2015-03-01 · Expand citations
  16. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. 2015-01-01 · Expand citations
  17. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. 2014-11-01 · Expand citations
  18. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. 2004-03-01 · Expand citations
  19. The pharmacology of psilocybin. 2002-10-01 · Expand citations
  20. 10.1002/0471667196.ess2478.pub2
  21. 10.1002/dta.1376
  22. 10.1007/s10508-019-01606-9
  23. 10.1007/s11930-023-00369-8
  24. 10.1016/j.addbeh.2017.05.005
  25. 10.1016/j.annepidem.2004.09.004
  26. 10.1016/j.drugalcdep.2019.107755
  27. 10.1016/j.drugpo.2017.06.011
  28. 10.1016/j.jbi.2008.08.010
  29. 10.1016/j.jbi.2019.103208
  30. 10.1016/j.mcna.2019.02.005
  31. 10.1016/j.paid.2018.04.030
  32. 10.1016/j.paid.2020.110048
  33. 10.1016/s0092-6566(03)00046-1
  34. 10.1017/cbo9780511812743
  35. 10.1037/0022-3514.93.6.1080
  36. 10.1037/0033-2909.129.5.674
  37. 10.1037/0033-2909.133.5.859
  38. 10.1037/a0038087
  39. 10.1037/adb0000468
  40. 10.1055/a-1310-3990
  41. 10.1080/00031305.2000.10474502
  42. 10.1080/00224499.2020.1768204
  43. 10.1080/00918369.2013.839919
  44. 10.1080/10826084.2021.1899225
  45. 10.1080/15534511003676441
  46. 10.1097/adm.0000000000000764
  47. 10.1111/1467-6494.00123
  48. 10.1111/j.1467-9280.2009.02333.x
  49. 10.1146/annurev.psych.093008.100352
  50. 10.1146/annurev.pu.14.050193.000441
  51. 10.1177/0013164419874494
  52. 10.1177/0269881108093587
  53. 10.1177/1088868307309606
  54. 10.1177/109019817400200405
  55. 10.1186/s12889-020-09210-6
  56. 10.1201/9781420010138
  57. 10.1353/hpu.2019.0089
  58. 10.1513/annalsats.201508-531ps
  59. 10.22459/bj.03.2014
  60. 10.2307/1268249
  61. 10.3109/10826084.2014.980954
  62. 10.37226/rcp.v4i2.2029
  63. 10.37226/rcp.v6i1.6325

Cited by — these papers cite this paper (0)

No citing papers identified in the available metadata. This does not establish that none exist.